Publications
139
Citations
330
Est. group size
~1
Recurring co-author estimate
Active years
10
Publishing since 2017
This researcher works in gastroenterology and cancer prevention, with a focus on stomach (gastric) diseases. A major theme is testing drugs and dietary compounds to prevent stomach cancer in people who already have precancerous changes, using rigorous randomized clinical trials. Related work touches on Helicobacter pylori infection (a bacterium linked to stomach disease) and cancer screening.
Publication activity grew sharply from a few papers per year through 2021 to over 25 per year on average in the last five years.
Generated by claude-opus-4-8 from public bibliographic data · Jul 11, 2026
- Safety and Efficacy of Eflornithine in Patients with Gastric Precancerous Lesions: A Double-Blinded, Randomized Clinical Trial
Cancer Prevention Research · 2026
- Supplementary Table S5 from Safety and Efficacy of Eflornithine in Patients with Gastric Precancerous Lesions: A Double-Blinded, Randomized Clinical Trial
2026
- Supplementary Table S9 from Safety and Efficacy of Eflornithine in Patients with Gastric Precancerous Lesions: A Double-Blinded, Randomized Clinical Trial
2026
- Supplementary Figure S1 from Safety and Efficacy of Eflornithine in Patients with Gastric Precancerous Lesions: A Double-Blinded, Randomized Clinical Trial
2026
- Supplementary Table S4 from Safety and Efficacy of Eflornithine in Patients with Gastric Precancerous Lesions: A Double-Blinded, Randomized Clinical Trial
2026
- Data from Safety and Efficacy of Eflornithine in Patients with Gastric Precancerous Lesions: A Double-Blinded, Randomized Clinical Trial
2026
- Supplementary Table S1 from Safety and Efficacy of Eflornithine in Patients with Gastric Precancerous Lesions: A Double-Blinded, Randomized Clinical Trial
2026
- Supplementary Table S7 from Safety and Efficacy of Eflornithine in Patients with Gastric Precancerous Lesions: A Double-Blinded, Randomized Clinical Trial
2026
- Supplementary Table S1 from Randomized, Double-Blind, Placebo-Controlled Trial of Meriva (Curcuminoids) as a Candidate Chemoprevention Agent for Gastric Carcinogenesis
2026
- Supplementary Figure S2 from Randomized, Double-Blind, Placebo-Controlled Trial of Meriva (Curcuminoids) as a Candidate Chemoprevention Agent for Gastric Carcinogenesis
2026
- Supplementary Table S3 from Safety and Efficacy of Eflornithine in Patients with Gastric Precancerous Lesions: A Double-Blinded, Randomized Clinical Trial
2026
- Data from Randomized, Double-Blind, Placebo-Controlled Trial of Meriva (Curcuminoids) as a Candidate Chemoprevention Agent for Gastric Carcinogenesis
2026
- Supplementary Table S11 from Safety and Efficacy of Eflornithine in Patients with Gastric Precancerous Lesions: A Double-Blinded, Randomized Clinical Trial
2026
- Supplementary Figure S4 from Randomized, Double-Blind, Placebo-Controlled Trial of Meriva (Curcuminoids) as a Candidate Chemoprevention Agent for Gastric Carcinogenesis
2026
- Supplementary Table S4 from Randomized, Double-Blind, Placebo-Controlled Trial of Meriva (Curcuminoids) as a Candidate Chemoprevention Agent for Gastric Carcinogenesis
2026
- The American Journal of Gastroenterology×38
- Gastroenterology×17
- Digestive Diseases and Sciences×5
- Gastroenterology Research×4
- Cancer Epidemiology Biomarkers & Prevention×3
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 11, 2026.
Claim or correct this profile